• 中国中文核心期刊
  • 中国科学引文数据库核心期刊
  • 中国科技核心期刊
  • 中国高校百佳科技期刊
高级检索

盐酸吡格列酮有关物质的色谱-质谱结构鉴定

殷潇雅, 汪澄, 明国军, 杭太俊

殷潇雅, 汪澄, 明国军, 杭太俊. 盐酸吡格列酮有关物质的色谱-质谱结构鉴定[J]. 中国药科大学学报, 2017, 48(6): 701-710. DOI: 10.11665/j.issn.1000-5048.20170611
引用本文: 殷潇雅, 汪澄, 明国军, 杭太俊. 盐酸吡格列酮有关物质的色谱-质谱结构鉴定[J]. 中国药科大学学报, 2017, 48(6): 701-710. DOI: 10.11665/j.issn.1000-5048.20170611
shu
YIN Xiaoya, WANG Cheng, MING Guojun, HANG Taijun. Identification of the related substances in pioglitazone hydrochloride by hyphenated LC-MS techniques[J]. Journal of China Pharmaceutical University, 2017, 48(6): 701-710. DOI: 10.11665/j.issn.1000-5048.20170611
Citation: YIN Xiaoya, WANG Cheng, MING Guojun, HANG Taijun. Identification of the related substances in pioglitazone hydrochloride by hyphenated LC-MS techniques[J]. Journal of China Pharmaceutical University, 2017, 48(6): 701-710. DOI: 10.11665/j.issn.1000-5048.20170611
shu

盐酸吡格列酮有关物质的色谱-质谱结构鉴定

  • 1.

    中国药科大学药物分析系

  • 2.

    江苏九阳生物制药有限公司

Identification of the related substances in pioglitazone hydrochloride by hyphenated LC-MS techniques

摘要

    摘要
  • 摘要: 采用色谱-质谱联用技术鉴定盐酸吡格列酮的有关物质。使用Ultimate XB-C18(250 mm×4.6 mm，5 μm)色谱柱，以甲醇-0.1%乙酸铵缓冲液为流动相，梯度洗脱，对盐酸吡格列酮有关物质进行分离；以电喷雾正离子化-飞行时间质谱法测定各有关物质［M+H］+母离子的准确质量和元素组成，三重四极质谱测定特征碎片离子，对有关物质进行分析鉴定。根据质谱分析结果，结合合成工艺与强制降解机制分析，检测并鉴定出11个主要有关物质(1个合成中间体、6个合成副产物、4个降解产物)，可为其生产工艺优化和质量控制提供理论参考。
    Abstract: To identify the related substances in pioglitazone hydrochloride by hyphenated LC-MS techniques, an Ultimate XB-C18(250 mm×4. 6 mm, 5 μm)column was used for separation of the related substances with methanol and 0. 1% ammonium acetate buffer as the mobile phases in gradient elution. Electrospray positive ionization high resolution TOF/MS was used for the determination of the accurate mass and elemental composition of parent［M+H］+ ions of the related substances, and triple quadrupole tandem mass spectrometry was employed for the product mass spectra determination. Eleven major related substances were detected and identified to be one synthesis intermediate, six by-products and four degradation products, by using LC-MS determination, spectra elucidation, and further synthetic process and stress degradation mechanisms analysis. The results are useful for pioglitazone hydrochloride manufacturing processes optimization and quality control.
    • HTML全文
    • 参考文献(19)
  • [1] Gillies PS,Dunn CJ.Pioglitazone[J].Drugs,2000,60(2):333-343.
    [2] Bajpeyi S, Pasarica M, Conley KE, et al. Pioglitazone-induced improvements in insulin sensitivity occur without concomitant changes in muscle mitochondrial function[J].Metab Clin Exp,2017,69:24-32.
    [3] Yasmin S,Jayaprakash V.Thiazolidinediones and PPAR orchestra as antidiabetic agents:from past to present[J].Eur J Med Chem,2017,126:879-893.
    [4] Berger JP,Akiyama TE,Meinke PT.PPARs:therapeutic targets for metabolic disease[J].Trends Pharmacol Sci,2005,26(5):244-251.
    [5] Smith U.Pioglitazone:mechanism of action[J].Int J Clin Pract Suppl,2001(121):13-18.
    [6] Derosa G.Efficacy and tolerability of pioglitazone in patients with type 2 diabetes mellitus:comparison with other oral antihyperglycaemic agents[J].Drugs,2010,70(15):1945-1961.
    [7] Qingju LI,Pengnuo LI,Tian C.Effects of treatment of pioglitazone combined with insulin on beta-cell function[J].J Med Forum,2005,26(1):32-34.
    [8] Stolar M.Safety and efficacy of pioglitazone/metformin combination therapy in treatment of type 2 diabetes:a rationale for earlier use[J].Clin Med Insights Ther,2009,1(3):445-451.
    [9] Sen S, Sinha S, Gupta K. Comparative evaluation of effects of combined oral anti-diabetic drugs(sulfonylurea plus pioglitazone and sulfonylurea plus metformin)over lipid parameters in type 2 diabetic patients[J].Int J Basic Clin Pharmacol,2013,2(3):257.
    [10] Srinivasulu D,Sastry BS,Prakash GO,et al.A new RP-HPLC method for separation and determination of process related impurities in pioglitazone hydrochloride API[J].J Sci Ind Res,2014,73(9):618-621.
    [11] Xun YB,Jiang LG,Kai D,et al.The related substances research and product evaluation for pioglitazone hydrochloride oral solid dosage form[J].Drug Stand China(中国药品标准),2011,12(6):450-454.
    [12] Rashmitha N, Rao CS, Chandra K, et al. A validated stability indicating HPLC method for the determination of impurities in pioglitazone hydrochloride[J].Der Pharma Chemica,2010,2(5):426-433.
    [13] Chinnalalaiah R, Pigili R, Avanapu SR. Liquid chromatography and tandem mass spectrometry method for quantitative determination of pioglitazone and its metabolite 5-hydroxy pioglitazone in human plasma[J].Ann Pharm Fr,2017,75(2):105-111.
    [14] Jagadeesh B,Bharathi D V,Pankaj C,et al.Development and validation of highly selective and robust method for simultaneous estimation of pioglitazone,hydroxypioglitazone and metformin in human plasma by LC-MS/MS:application to a pharmacokinetic study[J].J Chromatog B,2013,930:136-145.
    [15] Karraa VK,Pillia NR,Inamadugub JK,et al.Simultaneous determination of pioglitazone and candesartan in human plasma by LC-MS/MS and its application to a human pharmacokinetic study[J].J Pharm Anal,2012,02(3):167-173.
    [16] Ramulu K,Kumar TT,Krishna SR,et al.Identification,isolation and characterization of potential degradation products in pioglitazone hydrochloride drug substance[J].Pharmazie,2010,65(3):162-168.
    [17] ICH.Stability testing of new drug substances and products[EB/OL].http://www.ich.org/products/guidelines/quality/quality-single/article/stability-testing-of-new-drug-substances-and-products.html.
    [18] Ngwa G.Forced degradation as an integral part of HPLC stability-indicating method development[J].Drug Deliv Technol,2010,10(5):56-59.
    [19] Rawat T,Pandey IP.Forced degradation studies for drug substances and drug products-scientific and regulatory considerations[J].J Pharm Sci Res,2015,7(5):238-241.
    • 相关文章
    • 施引文献
    • 资源附件(0)
计量
  • 文章访问数: 
  • HTML全文浏览量:  0
  • PDF下载量: 
  • 被引次数: 0
出版历程
  • 刊出日期:  2017-12-24

目录

摘要
HTML全文
    参考文献(19)
    相关文章
    施引文献
    资源附件(0)

    /

    返回文章
    返回

    版权所有：《中国药科大学学报》编辑部苏ICP备05007142号

    地址：江苏省南京市鼓楼区童家巷24号（210009）电话: 025-83271566E-mail: xuebao@cpu.edu.cn

    本系统由 北京仁和汇智信息技术有限公司 开发  百度统计

    访问量：336219

    x 关闭 永久关闭